Evidence map›Paper›PMID 36908992›Full record

ArticleRoyal Society open science2023

Extreme value modelling of SARS-CoV-2 community transmission using discrete generalized Pareto distributions.

Abdelaati Daouia, Gilles Stupfler, Antoine Usseglio-Carleve

Open access · goldAbstract read
In one paragraph

Article in Royal Society open science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Abdelaati DaouiaToulouse School of Economics, University of Toulouse Capitole, Toulouse, France.ORCID 0000-0003-2621-8860
Gilles StupflerUniversity of Angers, CNRS, LAREMA, SFR MATHSTIC, 49000 Angers, France.ORCID 0000-0003-2497-9412
Antoine Usseglio-CarleveLaboratoire de Mathématiques d'Avignon UPR 2151, Avignon Université 84000 Avignon, France.ORCID 0000-0002-8148-3758
Centre National de la Recherche Scientifique · FRToulouse School of Economics · FRUniversité d'Avignon et des Pays de Vaucluse · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Superspreading has been suggested to be a major driver of overall transmission in the case of SARS-CoV-2. It is, therefore, important to statistically investigate the tail features of superspreading events (SSEs) to better understand virus propagation and control. Our extreme value analysis of different sources of secondary case data indicates that case numbers of SSEs associated with SARS-CoV-2 may be fat-tailed, although substantially less so than predicted recently in the literature, but also less important relative to SSEs associated with SARS-CoV. The results caution against pooling data from both coronaviruses. This could provide policy- and decision-makers with a more reliable assessment of the tail exposure to SARS-CoV-2 contamination. Going further, we consider the broader problem of large community transmission. We study the tail behaviour of SARS-CoV-2 cluster cases documented both in official reports and in the media. Our results suggest that the observed cluster sizes have been fat-tailed in the vast majority of surveyed countries. We also give estimates and confidence intervals of the extreme potential risk for those countries. A key component of our methodology is up-to-date discrete generalized Pareto models which allow for maximum likelihood-based inference of data with a high degree of discreteness.

Indexed as

cluster sizeCOVID-19discrete extremesextreme value theorysecondary casessuperspreading

Identifiers

PMID36908992
PMCPMC9993046
OpenAlexW4323566476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.